Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in Hyderabad, Telangana. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients (APIs), and exports to numerous countries across the world. It is among the larger pharmaceutical firms in India by revenue.
| Field | Details |
|---|---|
| Type | Public company |
| Industry | Pharmaceuticals |
| Headquarters | Hyderabad, Telangana, India |
| Founded | 1986 |
| Founders | P. V. Ramprasad Reddy, K. Nityananda Reddy and associates |
| Listed on | BSE, NSE |
| Country of origin | India |
Aurobindo Pharma was incorporated in 1986 and commenced operations in 1988–89 with a single unit producing semi-synthetic penicillins. The company is named after the philosopher and yogi Sri Aurobindo. Over time it expanded from API manufacturing into formulations, and built a presence in regulated markets including the United States and Europe.
The company operates manufacturing facilities and research and development centres in India, with several sites approved by international regulators such as the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). Its product portfolio spans multiple therapeutic areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-allergic medications.
Aurobindo Pharma's business is broadly organised across:
The company has expanded internationally through acquisitions and subsidiaries in Europe and North America, providing it with manufacturing, distribution, and marketing capabilities in those regions. It supplies generic medicines to public health programmes and private markets in numerous countries.
Aurobindo Pharma is recognised as one of India's prominent pharmaceutical exporters and a major supplier of generic medicines globally. The Indian pharmaceutical industry is a leading source of generic drugs internationally, and Aurobindo is among the firms that have contributed to this position, particularly in antiretroviral therapy supplies for HIV/AIDS treatment programmes in developing countries.